Table 1.
Patient demographic and clinical characteristics.
| Patient characteristics | N=98 |
|---|---|
| Male, (%) | 38 (39) |
| Age at start of ADM, median (IQR), years | 33 (26–47) |
| Disease durationa, median (IQR), years | 7 (2–14) |
| CD, (%) | 72 (73) |
| CD locationb, (%): L1;L2;L3 | 20/72 (28); 13/72 (18); 39/72 (54) |
| Upper GI CD (L4)b, (%) | 3/72 (4) |
| CD behaviorb, (%): B1;B2;B3 | 33/72 (46); 10/72 (14); 29/72 (40) |
| UC extentb, (%): E1;E2;E3 | 0/26 (0); 16/26 (62); 10/26 (28) |
| Perianal fistulising CD, (%) | 32/72 (44) |
| Prior ileocolonic resection, (%) | 28/72 (39) |
| Smoking ever, (%) | 34 (35) |
| ADM as first-line treatment, (%) | 55 (56) |
| Concomitant IMM, (%) | 26 (27) |
| ATA at first TDM (%) | 12 (12) |
| ADM dosing other than 40mg eow at first TDM, (%) | 36/95 (38) |
| Reactive TDM | 56 (57) |
a
From diagnosis to start of ADM
b
Montreal classification.
ATA: antibodies to adalimumab; CD: Crohn’s disease; UC: ulcerative colitis; ADM: adalimumab; TDM: therapeutic drug monitoring; IMM: immunomodulators; IQR: interquartile range; GI: gastrointestinal; eow: every other week.